Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease (Q81951210)
Jump to navigation
Jump to search
scientific article published on 10 September 2008
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease |
scientific article published on 10 September 2008 |
Statements
Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease (English)
Norihiro Nishimoto
Kimio Terao
Toru Mima
Hideko Nakahara
Nobuhiro Takagi
10 September 2008